SYRS
Syros Pharmaceuticals, Inc.
Price Chart
Latest Quote
$0.00
-0.00 (-42.86%)
Current Price
| Previous Close | $0.00 |
| Open | $0.00 |
| Day High | $0.00 |
| Day Low | $0.00 |
| Volume | 904 |
Stock Information
| Shares Outstanding | 26.83M |
| Total Debt | $60.23M |
| Cash Equivalents | $58.27M |
| Revenue | $386K |
| Net Income | $-97.81M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $5K |
| EPS (TTM) | $-3.07 |
| Exchange | PNK |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.96M |
| Sales | $386K |
| Income | $-97.81M |
| Book/sh | $-0.41 |
| Cash/sh | $2.17 |
| Employees | 68 |
Financial Ratios
| Quick Ratio | 2.05 |
| Current Ratio | 2.25 |
Returns & Margins
| ROA | -59.88% |
| ROE | -776.96% |
| Operating Margin | -28891.71% |
Ownership
| Insider Ownership | 0.15% |
| Institutional Ownership | 9.62% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.00 |
| P/S | 0.01 |
| P/B | -0.00 |
Analyst Data
| Recommendation | none |
| Target Price | $8.75 |
Technical Indicators
| SMA20 | $0.00 |
| SMA50 | $0.00 |
| SMA200 | $0.00 |
| RSI | 50.00 |
| ATR | 0.0001 |
| Shares Float | 26.82M |
| Short Float | 3.81% |
| Short Ratio | 0.80 |
| Volatility | 1.27 |
| Rel Volume | 0.43 |
Performance History
| Week | +0.00% |
| Month | -50.00% |
| Quarter | +0.00% |
| 6 Months | -60.00% |
| YTD | +0.00% |
| Year | -99.23% |
| 3 Years | -99.99% |
| 5 Years | -100.00% |
| 10 Years | -100.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-04 | $0.00 | 5,369 |
| 2026-06-03 | $0.00 | 2,771 |
| 2026-06-02 | $0.00 | 0 |
| 2026-06-01 | $0.00 | 65,712 |
| 2026-05-29 | $0.00 | 2,799 |
| 2026-05-28 | $0.00 | 5,388 |
| 2026-05-27 | $0.00 | 1,911 |
| 2026-05-26 | $0.00 | 8,096 |
| 2026-05-22 | $0.00 | 14,208 |
| 2026-05-21 | $0.00 | 43,752 |
| 2026-05-20 | $0.00 | 622 |
| 2026-05-19 | $0.00 | 1,650 |
| 2026-05-18 | $0.00 | 2,665 |
| 2026-05-15 | $0.00 | 1,724 |
| 2026-05-14 | $0.00 | 22,692 |
| 2026-05-13 | $0.00 | 31,462 |
| 2026-05-12 | $0.00 | 30,367 |
| 2026-05-11 | $0.00 | 1,175 |
| 2026-05-08 | $0.00 | 1,893 |
| 2026-05-07 | $0.00 | 2,837 |
| 2026-05-06 | $0.00 | 9,726 |
About Syros Pharmaceuticals, Inc.
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
đ° Latest News
No news articles available at the moment. Check back later for updates on SYRS.
Period:
Loading...
Income Statement (Annual)
| Metric | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| Revenue | |||
| Total Revenue | $9,936,000 | $14,880,000 | $23,488,000 |
| Operating Revenue | $9,936,000 | $14,880,000 | $23,488,000 |
| Expenses | |||
| Interest Expense | $5,127,000 | $4,134,000 | $3,907,000 |
| Total Expenses | $136,435,000 | $141,243,000 | $122,908,000 |
| Other Income Expense | $-39,764,000 | $33,711,000 | $16,682,000 |
| Net Non Operating Interest Income Expense | $1,689,000 | $-2,002,000 | $-3,820,000 |
| Interest Expense Non Operating | $5,127,000 | $4,134,000 | $3,907,000 |
| Operating Expense | $136,435,000 | $141,243,000 | $122,908,000 |
| General And Administrative Expense | $28,282,000 | $29,299,000 | $23,036,000 |
| Other Non Operating Income Expenses | - | $-9,510,000 | - |
| Income & Earnings | |||
| Net Income From Continuing Operation Net Minority Interest | $-164,574,000 | $-94,654,000 | $-86,558,000 |
| Net Interest Income | $1,689,000 | $-2,002,000 | $-3,820,000 |
| Interest Income | $6,816,000 | $2,132,000 | $87,000 |
| Normalized Income | $-124,810,000 | $-128,365,000 | $-103,240,000 |
| Net Income From Continuing And Discontinued Operation | $-164,574,000 | $-94,654,000 | $-86,558,000 |
| Total Operating Income As Reported | $-128,988,000 | $-135,873,000 | $-99,420,000 |
| Net Income Common Stockholders | $-164,574,000 | $-94,654,000 | $-86,558,000 |
| Net Income | $-164,574,000 | $-94,654,000 | $-86,558,000 |
| Net Income Including Noncontrolling Interests | $-164,574,000 | $-94,654,000 | $-86,558,000 |
| Net Income Continuous Operations | $-164,574,000 | $-94,654,000 | $-86,558,000 |
| Pretax Income | $-164,574,000 | $-94,654,000 | $-86,558,000 |
| Special Income Charges | $-2,489,000 | $-9,510,000 | $0 |
| Interest Income Non Operating | $6,816,000 | $2,132,000 | $87,000 |
| Operating Income | $-126,499,000 | $-126,363,000 | $-99,420,000 |
| Per Share | |||
| Diluted EPS | $-5.81 | $-7.49 | $-13.84 |
| Basic EPS | $-5.81 | $-7.49 | $-13.84 |
| Other | |||
| Tax Effect Of Unusual Items | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-117,431,000 | $-121,525,000 | $-96,315,000 |
| Total Unusual Items | $-39,764,000 | $33,711,000 | $16,682,000 |
| Total Unusual Items Excluding Goodwill | $-39,764,000 | $33,711,000 | $16,682,000 |
| Reconciled Depreciation | $2,252,000 | $2,706,000 | $3,018,000 |
| EBITDA (Bullshit earnings) | $-157,195,000 | $-87,814,000 | $-79,633,000 |
| EBIT | $-159,447,000 | $-90,520,000 | $-82,651,000 |
| Diluted Average Shares | $28,325,779 | $12,631,968 | $6,253,498 |
| Basic Average Shares | $28,325,779 | $12,631,968 | $6,253,498 |
| Diluted NI Availto Com Stockholders | $-164,574,000 | $-94,654,000 | $-86,558,000 |
| Restructuring And Mergern Acquisition | $2,489,000 | $9,510,000 | $0 |
| Gain On Sale Of Security | $-37,275,000 | $43,221,000 | $16,682,000 |
| Research And Development | $108,153,000 | $111,944,000 | $99,872,000 |
| Selling General And Administration | $28,282,000 | $29,299,000 | $23,036,000 |
| Other Gand A | $28,282,000 | $29,299,000 | $23,036,000 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| Assets | |||
| Net Tangible Assets | $16,662,000 | $127,736,000 | $85,218,000 |
| Total Assets | $168,174,000 | $244,486,000 | $182,935,000 |
| Total Non Current Assets | $23,194,000 | $33,094,000 | $46,350,000 |
| Other Non Current Assets | $3,711,000 | $8,434,000 | $6,027,000 |
| Current Assets | $144,980,000 | $211,392,000 | $136,585,000 |
| Other Current Assets | $5,454,000 | $7,394,000 | $3,237,000 |
| Receivables | $0 | $1,694,000 | $2,979,000 |
| Cash Cash Equivalents And Short Term Investments | $139,526,000 | $202,304,000 | $130,369,000 |
| Cash And Cash Equivalents | $139,526,000 | $167,467,000 | $92,302,000 |
| Investmentin Financial Assets | - | $0 | $13,038,000 |
| Other Receivables | - | $1,694,000 | $2,979,000 |
| Prepaid Assets | - | - | $3,237,000 |
| Accounts Receivable | - | - | $0 |
| Debt | |||
| Total Debt | $62,075,000 | $63,571,000 | $65,191,000 |
| Long Term Debt And Capital Lease Obligation | $53,084,000 | $61,500,000 | $63,180,000 |
| Long Term Debt | $34,556,000 | $40,649,000 | $40,257,000 |
| Current Debt And Capital Lease Obligation | $8,991,000 | $2,071,000 | $2,011,000 |
| Current Debt | $6,667,000 | - | - |
| Other Current Borrowings | $6,667,000 | - | - |
| Liabilities | |||
| Total Liabilities Net Minority Interest | $151,512,000 | $116,750,000 | $97,717,000 |
| Total Non Current Liabilities Net Minority Interest | $114,831,000 | $85,972,000 | $66,209,000 |
| Other Non Current Liabilities | $61,747,000 | $24,472,000 | $3,029,000 |
| Derivative Product Liabilities | $61,747,000 | $24,472,000 | $3,029,000 |
| Current Liabilities | $36,681,000 | $30,778,000 | $31,508,000 |
| Current Deferred Liabilities | $0 | $4,330,000 | $10,181,000 |
| Payables And Accrued Expenses | $20,697,000 | $15,848,000 | $12,972,000 |
| Payables | $11,544,000 | $6,411,000 | $3,692,000 |
| Accounts Payable | $11,544,000 | $6,411,000 | $3,692,000 |
| Non Current Deferred Liabilities | - | - | $0 |
| Equity | |||
| Common Stock Equity | $16,662,000 | $127,736,000 | $85,218,000 |
| Total Equity Gross Minority Interest | $16,662,000 | $127,736,000 | $85,218,000 |
| Stockholders Equity | $16,662,000 | $127,736,000 | $85,218,000 |
| Gains Losses Not Affecting Retained Earnings | $0 | $102,000 | $-79,000 |
| Retained Earnings | $-722,807,000 | $-558,233,000 | $-463,579,000 |
| Other Equity Adjustments | - | $102,000 | $-79,000 |
| Other | |||
| Ordinary Shares Number | $26,448,678 | $20,263,116 | $6,202,403 |
| Share Issued | $26,448,678 | $20,263,116 | $6,202,403 |
| Tangible Book Value | $16,662,000 | $127,736,000 | $85,218,000 |
| Invested Capital | $57,885,000 | $168,385,000 | $125,475,000 |
| Working Capital | $108,299,000 | $180,614,000 | $105,077,000 |
| Capital Lease Obligations | $20,852,000 | $22,922,000 | $24,934,000 |
| Total Capitalization | $51,218,000 | $168,385,000 | $125,475,000 |
| Additional Paid In Capital | $739,443,000 | $685,847,000 | $548,870,000 |
| Capital Stock | $26,000 | $20,000 | $6,000 |
| Common Stock | $26,000 | $20,000 | $6,000 |
| Preferred Stock | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $18,528,000 | $20,851,000 | $22,923,000 |
| Current Deferred Revenue | $0 | $4,330,000 | $10,181,000 |
| Current Capital Lease Obligation | $2,324,000 | $2,071,000 | $2,011,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $6,993,000 | $8,529,000 | $6,344,000 |
| Current Accrued Expenses | $9,153,000 | $9,437,000 | $9,280,000 |
| Net PPE | $19,483,000 | $24,660,000 | $27,285,000 |
| Accumulated Depreciation | $-7,634,000 | $-12,555,000 | $-9,856,000 |
| Gross PPE | $27,117,000 | $37,215,000 | $37,141,000 |
| Leases | $11,657,000 | $11,657,000 | $11,657,000 |
| Other Properties | $12,185,000 | $22,447,000 | $22,430,000 |
| Machinery Furniture Equipment | $3,275,000 | $3,111,000 | $3,054,000 |
| Properties | $0 | $0 | $0 |
| Other Short Term Investments | $0 | $34,837,000 | $38,067,000 |
| Investments And Advances | - | $0 | $13,038,000 |
| Non Current Deferred Revenue | - | - | $0 |
| Available For Sale Securities | - | - | $13,038,000 |
| Construction In Progress | - | - | $0 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| Free Cash Flow | |||
| Free Cash Flow | $-109,979,000 | $-124,306,000 | $-100,785,000 |
| Operating Activities | |||
| Operating Cash Flow | $-109,707,000 | $-123,065,000 | $-99,540,000 |
| Cash Flow From Continuing Operating Activities | $-109,707,000 | $-123,065,000 | $-99,540,000 |
| Operating Gains Losses | $37,275,000 | $-38,206,000 | $-16,682,000 |
| Investing Activities | |||
| Capital Expenditure | $-272,000 | $-1,241,000 | $-1,245,000 |
| Investing Cash Flow | $37,337,000 | $67,185,000 | $-52,653,000 |
| Cash Flow From Continuing Investing Activities | $37,337,000 | $67,185,000 | $-52,653,000 |
| Financing Activities | |||
| Repurchase Of Capital Stock | $0 | $-81,000 | - |
| Issuance Of Capital Stock | $43,270,000 | $119,761,000 | $70,337,000 |
| Financing Cash Flow | $43,462,000 | $131,045,000 | $70,511,000 |
| Cash Flow From Continuing Financing Activities | $43,462,000 | $131,045,000 | $70,511,000 |
| Net Common Stock Issuance | $43,270,000 | $119,680,000 | $70,337,000 |
| Common Stock Issuance | $43,270,000 | $119,761,000 | $70,337,000 |
| Net Other Financing Charges | - | $11,438,000 | $-41,000 |
| Net Preferred Stock Issuance | - | - | $0 |
| Preferred Stock Issuance | - | - | $0 |
| Other | |||
| Repayment Of Debt | $-65,000 | $-291,000 | $-265,000 |
| Interest Paid Supplemental Data | $4,552,000 | $3,408,000 | $3,191,000 |
| Income Tax Paid Supplemental Data | $0 | $0 | $0 |
| End Cash Position | $141,645,000 | $170,553,000 | $95,388,000 |
| Beginning Cash Position | $170,553,000 | $95,388,000 | $177,070,000 |
| Changes In Cash | $-28,908,000 | $75,165,000 | $-81,682,000 |
| Proceeds From Stock Option Exercised | $257,000 | $218,000 | $480,000 |
| Common Stock Payments | $0 | $-81,000 | - |
| Net Issuance Payments Of Debt | $-65,000 | $-291,000 | $-265,000 |
| Net Long Term Debt Issuance | $-65,000 | $-291,000 | $-265,000 |
| Long Term Debt Payments | $-65,000 | $-291,000 | $-265,000 |
| Net Investment Purchase And Sale | $36,049,000 | $68,426,000 | $-51,408,000 |
| Sale Of Investment | $87,017,000 | $68,426,000 | $0 |
| Purchase Of Investment | $-50,968,000 | $0 | $-51,408,000 |
| Net PPE Purchase And Sale | $1,288,000 | $-1,241,000 | $-1,245,000 |
| Sale Of PPE | $1,560,000 | $0 | $0 |
| Purchase Of PPE | $-272,000 | $-1,241,000 | $-1,245,000 |
| Change In Working Capital | $5,055,000 | $-5,517,000 | $-10,602,000 |
| Change In Other Working Capital | $-4,330,000 | $-5,851,000 | $-12,641,000 |
| Change In Other Current Liabilities | $-959,000 | $-848,000 | - |
| Change In Other Current Assets | $3,756,000 | $-2,407,000 | $-1,196,000 |
| Change In Payables And Accrued Expense | $2,954,000 | $5,111,000 | $4,878,000 |
| Change In Accrued Expense | $-2,179,000 | $2,345,000 | $4,830,000 |
| Change In Payable | $5,133,000 | $2,766,000 | $48,000 |
| Change In Account Payable | $5,133,000 | $2,766,000 | $48,000 |
| Change In Prepaid Assets | $1,940,000 | $-2,807,000 | $-995,000 |
| Change In Receivables | $1,694,000 | $1,285,000 | $-648,000 |
| Other Non Cash Items | $650,000 | $953,000 | $706,000 |
| Stock Based Compensation | $10,434,000 | $11,410,000 | $10,354,000 |
| Asset Impairment Charge | $515,000 | $0 | - |
| Amortization Of Securities | $-1,314,000 | $243,000 | $224,000 |
| Depreciation Amortization Depletion | $2,252,000 | $2,706,000 | $3,018,000 |
| Depreciation And Amortization | $2,252,000 | $2,706,000 | $3,018,000 |
| Gain Loss On Investment Securities | $37,275,000 | $-38,206,000 | $-16,682,000 |
| Net Income From Continuing Operations | $-164,574,000 | $-94,654,000 | $-86,558,000 |
| Issuance Of Debt | - | $0 | $0 |
| Long Term Debt Issuance | - | $0 | $0 |
| Changes In Account Receivables | - | $0 | $7,000 |
| Depreciation | - | $2,967,000 | $3,018,000 |
| Gain Loss On Sale Of PPE | - | - | $0 |
Fetched: 2026-02-02